InSysBio to launch Immune Response Template 3.4.0

March 30, 2021

March 30, 2021

IRT gets new data and recalculated parameters

[Moscow – 30.03.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.4.0. IRT represents a Quantitative Systems Pharmacology (QSP) platform of immune system simultaneously being a tool for development of models related to immune system. IRT is based on two main components. On the one hand, it is a fully-fledged database including a wide variety of features covering the immune system. On the other hand, it comprises Navigator that provides intuitive interface to interact with IRT Database. Thus, a modeler can apply calibrated sub-models exported from IRT as building blocks to simplify the model development process.

Now IRT gets a new portion of data and significant upgrade:

  • New cell cycle templates were added: Tc1, Tc9, Tc17
  • Surface molecules interactions in Immunological Synapse are now described on the surface instead of volume
  • Parameters for molecules interactions in Immunological Synapse were recalculated
  • NK cell cycle parameters were reestimated

IRT is one of InSysBio’s software tools being under constant development and upgrade for both internal and external usage. Its fundamental objective is to facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas.

To learn the full content of Immune Response Template 3.4.0, please visit

To get demo access to IRT version 3, please click “sign in” or “user account” on the

To get more information on any tool or leave your feedback, please feel free to contact us:

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit